Immune checkpoint inhibitors and cancer-related cognitive decline: a propensity score matched analysis in active chemotherapy patients
BackgroundWe investigated whether 1-year trajectories of cancer-related cognitive decline (CRCD) would be different in patients with chemotherapy combined with immune checkpoint inhibitors (chemoICI group) as compared with chemotherapy alone (chemo gro…